Skip to main content

Imaging and dosimetry for radionuclide based therapy

EJNMMI Physics welcomes submissions on imaging and dosimetry for radionuclide-based therapy. Radionuclide therapy and molecular radiotherapy are established modalities for the treatment of certain cancer types. In recent years there has been a significant expansion of new therapy options, radiopharmaceuticals and applications. Dosimetry is an essential component in the treatment chain to maximize the delivered absorbed dose to cancerous tissue while minimizing the dose to healthy organs. 

To highlight the rapid changes in this field and to address the remaining challenges, EJNMMI Physics is publishing an article collection on this topic. For this collection, we invite contributions on the many different aspects of imaging and dosimetry of radionuclides for therapeutic use. 

This collection will describe recent advances in the field and the manuscripts can be state-of-the-art review papers or original research papers. These papers can have a multi-disciplinary approach but the primary focus should be on medical physics or engineering related aspects.

Guest Editors
Hugo De Jong, University of Utrecht, Utrecht, Netherlands
Yuni Dewaraja, University of Michigan Medical School, Ann Arbor, United States
Gerhard Glatting, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
Michael Ljungberg, Lund University, Lund, Sweden

For editorial enquiries please contact

  1. Dosimetry-based personalized therapy was shown to have clinical benefits e.g. in liver selective internal radiation therapy (SIRT). Yet, there is no consensus about its introduction into clinical practice, mai...

    Authors: Francesca De Benetti, Julia Brosch-Lenz, Jorge Mario Guerra González, Carlos Uribe, Matthias Eiber, Nassir Navab and Thomas Wendler
    Citation: EJNMMI Physics 2024 11:51
  2. To investigate the optimal threshold for measuring thyroid volume in patients with Grave's hyperthyroidism (GH) by SPECT/CT.

    Authors: Chengpeng Gong, Yajing Zhang, Fei Feng, Mengmeng Hu, Kun Li, Rundong Pi, Hua Shu, Rongmei Tang, Xiaoli Wang, Shilin Tan, Fan Hu and Jia Hu
    Citation: EJNMMI Physics 2024 11:4
  3. Over recent years, [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy have evolved as a promising treatment option for advanced prostate cancer. Especially for alpha particle emitter treatments, there ...

    Authors: Mikhail Rumiantcev, Wei Bo Li, Simon Lindner, Grigory Liubchenko, Sandra Resch, Peter Bartenstein, Sibylle I. Ziegler, Guido Böning and Astrid Delker
    Citation: EJNMMI Physics 2023 10:53
  4. 177Lu-PSMA therapy has been successfully used to prolong the survival of patients with metastatic castration-resistant prostate cancer. Patient-specific dosimetry based on serial quantitative SPECT/CT imaging can...

    Authors: Sandra Resch, Sarah Takayama Fouladgar, Mathias Zacherl, Gabriel T. Sheikh, Grigory Liubchenko, Mikhail Rumiantcev, Lena M. Unterrainer, Vera Wenter, Peter Bartenstein, Sibylle I. Ziegler, Harun Ilhan, Leonie Beyer, Guido Böning and Astrid Delker
    Citation: EJNMMI Physics 2023 10:11
  5. Conventional calibration of the gamma camera consists of the calculation of calibration factors (CFs) (ratio of counts/cc and true concentration activity) as the function of the volume of interest (VOI). Howev...

    Authors: Stanislav Raskin, Dan Gamliel, David Abookasis, Simona Ben-Haim and Alexandre Chicheportiche
    Citation: EJNMMI Physics 2023 10:5
  6. Accurate quantification of radioactivity in a source of interest relies on accurate registration between SPECT and anatomical images, and appropriate correction of partial volume effects (PVEs). For small volu...

    Authors: Lily Carnegie-Peake, Jan Taprogge, Iain Murray, Glenn D. Flux and Jonathan Gear
    Citation: EJNMMI Physics 2022 9:86
  7. Dead-time correction is required for accurate quantitative SPECT-based dosimetry in the context of personalised 177Lu radiopharmaceutical therapy. We aimed to evaluate the impact of applying dead-time correction ...

    Authors: Alessandro Desy, Guillaume F. Bouvet, Nancy Lafrenière, Atefeh Zamanian, Philippe Després and Jean-Mathieu Beauregard
    Citation: EJNMMI Physics 2022 9:54
  8. Lead-212 (212Pb) is a promising radionuclide for targeted therapy, as it decays to α-particle emitter bismuth-212 (212Bi) via β-particle emission. This extends the problematic short half-life of 212Bi. In prepara...

    Authors: Monika Kvassheim, Mona-Elisabeth R. Revheim and Caroline Stokke
    Citation: EJNMMI Physics 2022 9:52

    The Correction to this article has been published in EJNMMI Physics 2022 9:71

  9. Accurate QSPECT is crucial in dosimetry-based, personalized radiopharmaceutical therapy with 177Lu and other radionuclides. We compared the quantitative performance of three NaI(Tl)-crystal SPECT/CT systems equip...

    Authors: Alessandro Desy, Guillaume F. Bouvet, Étienne Croteau, Nancy Lafrenière, Éric E. Turcotte, Philippe Després and Jean-Mathieu Beauregard
    Citation: EJNMMI Physics 2021 8:73
  10. Following each cycle of peptide receptor radionuclide therapy (PRRT), absorbed doses by tumors and normal organs are typically calculated from three quantitative single-photon emission computed tomography (SPE...

    Authors: Alexandre Chicheportiche, Moshe Sason, Jeremy Godefroy, Yodphat Krausz, Mahmoud Zidan, Kira Oleinikov, Amichay Meirovitz, David J. Gross, Simona Grozinsky-Glasberg and Simona Ben-Haim
    Citation: EJNMMI Physics 2021 8:63
  11. PET imaging of 90Y-microsphere distribution following radioembolisation is challenging due to the count-starved statistics from the low branching ratio of e+/e pair production during 90Y decay. PET systems using...

    Authors: Joey Labour, Philippe Boissard, Thomas Baudier, Fouzi Khayi, David Kryza, Pascale Veyrat Durebex, Sandrine Parisse-Di Martino, Thomas Mognetti, David Sarrut and Jean-Noël Badel
    Citation: EJNMMI Physics 2021 8:56
  12. 211At is one of the ideal nuclides for targeted radionuclide therapies (TRTs). Meta-[211At]astatobenzylguanidine (211At-MABG) has been proposed for the treatment of pheochromocytoma. To effectively use these radi...

    Authors: Naoyuki Ukon, Songji Zhao, Kohshin Washiyama, Noboru Oriuchi, Chengbo Tan, Saki Shimoyama, Miho Aoki, Hitoshi Kubo, Kazuhiro Takahashi and Hiroshi Ito
    Citation: EJNMMI Physics 2020 7:58
  13. Dosimetry after peptide receptor radionuclide therapy (PRRT) is increasing; however, comparing or pooling of dosimetric results can be challenging since different approaches are used. The aim of this study was...

    Authors: Daphne M. V. Huizing, Steffie M. B. Peters, Michelle W. J. Versleijen, Esther Martens, Marcel Verheij, Michiel Sinaasappel, Marcel P. M. Stokkel and Berlinda J. de Wit-van der Veen
    Citation: EJNMMI Physics 2020 7:36
  14. After each cycle of [177Lu]-DOTA-TATE peptide receptor radionuclide therapy (PRRT) dosimetry is performed to enable precise calculation of the radiation-absorbed dose to tumors and normal organs. Absorbed doses a...

    Authors: Alexandre Chicheportiche, Simona Ben-Haim, Simona Grozinsky-Glasberg, Kira Oleinikov, Amichay Meirovitz, David J. Gross and Jeremy Godefroy
    Citation: EJNMMI Physics 2020 7:5
  15. The aim of this study was to evaluate the predictive power of the absorbed dose to kidneys after the first course of treatment with [177Lu]-DOTA-TATE for neuroendocrine tumors (NETs) on the cumulative kidney abso...

    Authors: Alexandre Chicheportiche, Simona Grozinsky-Glasberg, David J. Gross, Yodphat Krausz, Asher Salmon, Amichay Meirovitz, Nanette Freedman and Jeremy Godefroy
    Citation: EJNMMI Physics 2018 5:36
  16. Rhenium-188-labelled-Lipiodol radioembolization is a safe and cost-effective treatment for primary liver cancer. In order to determine correlations between treatment doses and patient response to therapy, accu...

    Authors: Pedro L. Esquinas, Ajit Shinto, Koramadai K. Kamaleshwaran, Jephy Joseph and Anna Celler
    Citation: EJNMMI Physics 2018 5:30
  17. Generation of a SPECT scan during procedure may aid in the optimization of treatments as liver radioembolization by offering image-guided dosimetry. This, however, requires both shortened acquisition times and...

    Authors: Martijn M. A. Dietze, Sandra van der Velden, Marnix G. E. H. Lam, Max A. Viergever and Hugo W. A. M. de Jong
    Citation: EJNMMI Physics 2018 5:28
  18. The purpose was to validate 90Y PET gradient-based tumor segmentation in phantoms and to evaluate the impact of the segmentation method on reported tumor absorbed dose (AD) and biological effective dose (BED) in

    Authors: Justin K. Mikell, Ravi K. Kaza, Peter L. Roberson, Kelly C. Younge, Ravi N. Srinivasa, Bill S. Majdalany, Kyle C. Cuneo, Dawn Owen, Theresa Devasia, Matthew J. Schipper and Yuni K. Dewaraja
    Citation: EJNMMI Physics 2018 5:31
  19. Radioembolization is an established treatment for chemoresistant and unresectable liver cancers. Currently, treatment planning is often based on semi-empirical methods, which yield acceptable toxicity profiles...

    Authors: Remco Bastiaannet, S. Cheenu Kappadath, Britt Kunnen, Arthur J. A. T. Braat, Marnix G. E. H. Lam and Hugo W. A. M. de Jong
    Citation: EJNMMI Physics 2018 5:22
  20. Routine dosimetry is essential for personalized 177Lu-octreotate peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs), but practical and robust dosimetry methods are needed for wide clinic...

    Authors: Michela Del Prete, Frédéric Arsenault, Nassim Saighi, Wei Zhao, François-Alexandre Buteau, Anna Celler and Jean-Mathieu Beauregard
    Citation: EJNMMI Physics 2018 5:25
  21. This inter-comparison exercise was performed to demonstrate the variability of quantitative SPECT/CT imaging for lutetium-177 (177Lu) in current clinical practice. Our aim was to assess the feasibility of using i...

    Authors: Jill Wevrett, Andrew Fenwick, James Scuffham, Lena Johansson, Jonathan Gear, Susanne Schlögl, Marcel Segbers, Katarina Sjögreen-Gleisner, Pavel Solný, Michael Lassmann, Jill Tipping and Andrew Nisbet
    Citation: EJNMMI Physics 2018 5:17
  22. Peptide receptor radionuclide therapy (PRRT) with [177Lu]-DOTA-TATE is an effective treatment of neuroendocrine tumors (NETs). After each cycle of treatment, patient dosimetry evaluates the radiation dose to the ...

    Authors: Alexandre Chicheportiche, Faozi Artoul, Arnon Schwartz, Simona Grozinsky-Glasberg, Amichay Meirovitz, David J. Gross and Jeremy Godefroy
    Citation: EJNMMI Physics 2018 5:10
  23. SPECT quantification is important for dosimetry in targeted radionuclide therapy (TRT) and the calibration of SPECT images is a crucial stage for image quantification. The current standardized calibration prot...

    Authors: Adrien Halty, Jean-Noël Badel, Olga Kochebina and David Sarrut
    Citation: EJNMMI Physics 2018 5:11
  24. Camera calibration, which translates reconstructed count map into absolute activity map, is a prerequisite procedure for quantitative SPECT imaging. Both planar and tomographic scans using different phantom ge...

    Authors: Wei Zhao, Pedro L. Esquinas, Xinchi Hou, Carlos F. Uribe, Marjorie Gonzalez, Jean-Mathieu Beauregard, Yuni K. Dewaraja and Anna Celler
    Citation: EJNMMI Physics 2018 5:8
  25. Nuclear medicine imaging of neuroendocrine tumours is performed either by SPECT/CT imaging, using 111In-octreotide or by PET/CT imaging using 68Ga-radiolabelled somatostatin analogs. These imaging techniques will...

    Authors: L. Jönsson, A. Stenvall, E. Mattsson, E. Larsson, A. Sundlöv, T. Ohlsson and C. Hindorf
    Citation: EJNMMI Physics 2018 5:5

    The Correction to this article has been published in EJNMMI Physics 2022 9:76

  26. The aim of this study was to investigate the deadtime (DT) effects that are present in 177Lu images acquired after radionuclide therapy injection, assess differences in DT based on the full spectrum and the photo...

    Authors: Carlos F. Uribe, Pedro L. Esquinas, Marjorie Gonzalez, Wei Zhao, Jesse Tanguay and Anna Celler
    Citation: EJNMMI Physics 2018 5:2
  27. The European directive on basic safety standards (Council directive 2013/59 Euratom) mandates dosimetry-based treatment planning for radiopharmaceutical therapies. The directive comes into operation February 2...

    Authors: Caroline Stokke, Pablo Minguez Gabiña, Pavel Solný, Francesco Cicone, Mattias Sandström, Katarina Sjögreen Gleisner, Carlo Chiesa, Emiliano Spezi, Maria Paphiti, Mark Konijnenberg, Matt Aldridge, Jill Tipping, Michael Wissmeyer, Boudewijn Brans, Klaus Bacher, Carsten Kobe…
    Citation: EJNMMI Physics 2017 4:27
  28. In the planning of selective internal radiation therapy (SIRT) for liver cancer treatment, one major aspect is to determine the prescribed activity and to estimate the resulting absorbed dose inside normal liv...

    Authors: Nadine Spahr, Philipp Schilling, Smita Thoduka, Nasreddin Abolmaali and Andrea Schenk
    Citation: EJNMMI Physics 2017 4:25